Growth Hormone and Prolactin Secretion After Metoclopramide Administration (DA2 Receptor Blockade) in Fertile Women

Horm Metab Res. 2001 Sep;33(9):536-9. doi: 10.1055/s-2001-17214.

Abstract

In this report, we will describe the results of a cross-sectional study to assess PRL and GH secretion during the early follicular phase in 22 fertile patients after metoclopramide administration in order to achieve a dopaminergic DA2 receptor blockade. Blood samples were collected at - 15, 0, 15, 30, 45 and 60 minutes. PRL, GH, estradiol, IGF-I, TSH, glucose, and insulin were measured in the samples taken at - 15 and 0 minutes. The existence of a correlation between GH and PRL secretion was investigated. All patients presented normal serum levels of estradiol, prolactin, insulin, fasting glucose and IGF-I. Serum GH levels were not changed after metoclopramide infusion (p = 0.302), but there was a significant alteration in serum PRL (p = 0.0001) with the highest levels after 30 (mean: 237.20 ng/ml +/- 95.86) and 45 (mean: 211.80 ng/ml +/- 83.24) minutes. Serum GH levels did not correlate with serum PRL levels after the dopaminergic DA2 blockade. We conclude that GH secretion was not modulated by a direct effect of type 2 dopamine receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Cross-Sectional Studies
  • Dopamine D2 Receptor Antagonists*
  • Estradiol / blood
  • Female
  • Fertility*
  • Human Growth Hormone / blood
  • Human Growth Hormone / metabolism*
  • Humans
  • Insulin / blood
  • Insulin-Like Growth Factor I / analysis
  • Kinetics
  • Metoclopramide / pharmacology*
  • Obesity / blood
  • Prolactin / blood
  • Prolactin / metabolism*
  • Thyrotropin / blood

Substances

  • Blood Glucose
  • Dopamine D2 Receptor Antagonists
  • Insulin
  • Human Growth Hormone
  • Estradiol
  • Insulin-Like Growth Factor I
  • Prolactin
  • Thyrotropin
  • Metoclopramide